Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 10

    1.

    Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation.

    Bondong S, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E, Castillo-Tong DC, Cadron I, Vergote I, Braicu I, Sehouli J, Mahner S, Fogel M, Altevogt P.

    Ann Oncol. 2012 Jan 6. [Epub ahead of print]

    PMID:
    22228447
    [PubMed - as supplied by publisher]
    2.

    The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.

    Coley HM, Safuwan NA, Chivers P, Papacharalbous E, Giannopoulos T, Butler-Manuel S, Madhuri K, Lovell DP, Crook T.

    Br J Cancer. 2012 Jan 31;106(3):482-9. doi: 10.1038/bjc.2011.566. Epub 2012 Jan 10.

    PMID:
    22233925
    [PubMed - indexed for MEDLINE]
    3.

    Dietary fat intake and risk of ovarian cancer in the NIH-AARP Diet and Health Study.

    Blank MM, Wentzensen N, Murphy MA, Hollenbeck A, Park Y.

    Br J Cancer. 2012 Jan 31;106(3):596-602. doi: 10.1038/bjc.2011.572. Epub 2012 Jan 5.

    PMID:
    22223086
    [PubMed - indexed for MEDLINE]
    4.

    Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study.

    Trivers KF, Baldwin LM, Miller JW, Matthews B, Andrilla CH, Lishner DM, Goff BA.

    Cancer. 2011 Dec 1;117(23):5334-43. doi: 10.1002/cncr.26166. Epub 2011 Jul 25.

    PMID:
    21792861
    [PubMed - indexed for MEDLINE]
    5.

    Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment.

    Björklund M, Roos J, Gogvadze V, Shoshan M.

    Cancer Chemother Pharmacol. 2011 Dec;68(6):1459-67. Epub 2011 Apr 11.

    PMID:
    21479886
    [PubMed - indexed for MEDLINE]
    6.

    ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.

    Guan B, Wang TL, Shih IeM.

    Cancer Res. 2011 Nov 1;71(21):6718-27. Epub 2011 Sep 7.

    PMID:
    21900401
    [PubMed - indexed for MEDLINE]
    8.

    Error occurred: cannot get document summary

    PMID:
    22226807

    9.

    Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma.

    Martinez-Poveda B, Gomez V, Alcaide-German M, Perruca S, Vazquez S, Alba LE, Casanovas O, Garcia-Bermejo ML, Peso L, Jimenez B.

    Int J Oncol. 2011 Sep;39(3):543-52. doi: 10.3892/ijo.2011.1074. Epub 2011 Jun 9.

    PMID:
    21667025
    [PubMed - indexed for MEDLINE]
    10.

    Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

    Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.

    J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. Epub 2012 Jan 6.

    PMID:
    22228146
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk